Avalyn Pharma Inc. (NASDAQ:AVLN) Given Consensus Rating of “Buy” by Brokerages

Posted by Geri Gentry on Jun 23rd, 2026

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) have been assigned a consensus rating of “Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, two have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $59.00.

AVLN has been the topic of several recent analyst reports. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Evercore initiated coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 target price on the stock. Jefferies Financial Group initiated coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $52.00 target price on the stock. Morgan Stanley initiated coverage on shares of Avalyn Pharma in a research note on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 target price on the stock. Finally, Zacks Research upgraded shares of Avalyn Pharma to a “hold” rating in a report on Wednesday, May 27th.

Get Our Latest Stock Analysis on AVLN

Avalyn Pharma Trading Up 4.8%

Shares of AVLN opened at $32.97 on Tuesday. Avalyn Pharma has a twelve month low of $24.15 and a twelve month high of $33.19.

Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last announced its earnings results on Wednesday, June 3rd. The company reported ($21.83) earnings per share for the quarter, missing the consensus estimate of ($16.38) by ($5.45).

Insider Transactions at Avalyn Pharma

In related news, Director Jill Carroll purchased 277,778 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were purchased at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the acquisition, the director owned 2,186,562 shares in the company, valued at approximately $39,358,116. This trade represents a 14.55% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was bought at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the completion of the acquisition, the insider owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. The trade was a 34.06% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

About Avalyn Pharma

(Get Free Report)

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.